Silibinin Inhibits Causes Cell Cycle Arrest in Human Gastric Cancer MGC803 Cells Via STAT3 Pathway Inhibition

Gastric cancer (GC) is one of the highest cancermortality diseases with a high incidence rate (Chen et al., 2013), and is the second most common cause of death from cancer in Asia (Leung et al., 2008). Surgery is the cornerstone of the management of patients with resectable GC (Van et al., 2008). For patients with advanced stage GC which are not completely resected, the palliative chemotherapy is the main choice (Karpeh et al., 2013). But many chemicals or drugs have shown numerous side effects. Therefore, developing novel agents to prevent and treat GC specifically for advanced GC, would has potential clinical application value (Marzieh et al., 2013; Kazem et al., 2013). Numbers of recent studies have demonstrated that signal transducer and activator of transcription (STAT)-3 was constitutively active in various primary tumors and tumor cell lines such as breast cancer, prostate cancer, pancreatic adenocarcinoma, colon carcinoma, as well as GC, activated STAT3 was often associated with tumor invasiveness, metastasis and prognosis by enhancing cancer cells proliferation, survival, and angiogenesis (Yakata et al., 2007; Sato et al., 2011; Morikawa et al., 2011; Singh et al., 2012; Huang et al., 2012; Lee et al.,